Search Results - "Stewart, A. Keith"

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Philippe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth J.

“…Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can…”
Get full text

Carfilzomib by Kortuem, K. Martin, Stewart, A. Keith

“…This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for…”
Get full text

How Thalidomide Works Against Cancer by Stewart, A. Keith

“…The surprising ability of thalidomide and its analogs to treat various hematologic malignancies is through the loss of two transcription factors. [Also see…”
Get full text

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma by Leung-Hagesteijn, Chungyee, Erdmann, Natalie, Cheung, Grace, Keats, Jonathan J., Stewart, A. Keith, Reece, Donna E., Chung, Kim Chan, Tiedemann, Rodger E.

“…Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial. We report the existence of a progenitor organization in primary…”
Get full text

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide by Zhu, Yuan Xiao, Braggio, Esteban, Shi, Chang-Xin, Bruins, Laura A., Schmidt, Jessica E., Van Wier, Scott, Chang, Xiu-Bao, Bjorklund, Chad C., Fonseca, Rafael, Bergsagel, P. Leif, Orlowski, Robert Z., Stewart, A. Keith

“…The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects…”
Get full text

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation by PALUMBO, Antonio, VINCENT RAJKUMAR, S, DIMOPOULOS, Meletios A, RICHARDSON, Paul G, CAVO, Michele, SPENCER, Andrew, KEITH STEWART, A, SHIMIZU, Kazuyuki, LONIAL, Sagar, SONNEVELD, Pieter, DURIE, Brian G. M, MOREAU, Philippe, SAN MIGUEL, Jesus F, ORLOWSKI, Robert Z, LAROCCA, Alessandra, NIESVIZKY, Ruben, MORGAN, Gareth, LANDGREN, Ola, HAJEK, Roman, EINSELE, Hermann, ANDERSON, Kenneth C

“…To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. A…”
Get full text

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith, Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Phillipe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth

“…Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple…”
Get full text

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma by Zhu, Yuan Xiao, Kortuem, K. Martin, Stewart, A. Keith

“…Abstract Although several mechanisms have been proposed to explain the activity of thalidomide, lenalidomide and pomalidomide in multiple myeloma (MM),…”
Get full text

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by Siegel, David S., Martin, Thomas, Wang, Michael, Vij, Ravi, Jakubowiak, Andrzej J., Lonial, Sagar, Trudel, Suzanne, Kukreti, Vishal, Bahlis, Nizar, Alsina, Melissa, Chanan-Khan, Asher, Buadi, Francis, Reu, Frederic J., Somlo, George, Zonder, Jeffrey, Song, Kevin, Stewart, A. Keith, Stadtmauer, Edward, Kunkel, Lori, Wear, Sandra, Wong, Alvin F., Orlowski, Robert Z., Jagannath, Sundar

“…Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this…”
Get full text

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma by Lazzari, Elisa, Mondala, Phoebe K., Santos, Nathaniel Delos, Miller, Amber C., Pineda, Gabriel, Jiang, Qingfei, Leu, Heather, Ali, Shawn A., Ganesan, Anusha-Preethi, Wu, Christina N., Costello, Caitlin, Minden, Mark, Chiaramonte, Raffaella, Stewart, A.  Keith, Crews, Leslie A., Jamieson, Catriona H. M.

“…Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive…”
Get full text

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Palumbo, Antonio, Bringhen, Sara, Mateos, Maria-Victoria, Larocca, Alessandra, Facon, Thierry, Kumar, Shaji K., Offidani, Massimo, McCarthy, Philip, Evangelista, Andrea, Lonial, Sagar, Zweegman, Sonja, Musto, Pellegrino, Terpos, Evangelos, Belch, Andrew, Hajek, Roman, Ludwig, Heinz, Stewart, A. Keith, Moreau, Philippe, Anderson, Kenneth, Einsele, Hermann, Durie, Brian.G.M., Dimopoulos, Meletios A., Landgren, Ola, San Miguel, Jesus F., Richardson, Paul, Sonneveld, Pieter, Rajkumar, S. Vincent

“…We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been…”
Get full text

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma by Stewart, A. Keith, Rajkumar, S. Vincent, Dimopoulos, Meletios A, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David S, Mihaylov, Georgi G, Goranova-Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej J, San-Miguel, Jesus F, Ludwig, Heinz, Wang, Michael, Maisnar, Vladimír, Minarik, Jiri, Bensinger, William I, Mateos, Maria-Victoria, Ben-Yehuda, Dina, Kukreti, Vishal, Zojwalla, Naseem, Tonda, Margaret E, Yang, Xinqun, Xing, Biao, Moreau, Philippe, Palumbo, Antonio

“…In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with relapsed multiple…”
Get full text

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis by Mikhael, Joseph R., Schuster, Steven R., Jimenez-Zepeda, Victor H., Bello, Nancy, Spong, Jacy, Reeder, Craig B., Stewart, A. Keith, Bergsagel, P. Leif, Fonseca, Rafael

“…Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before…”
Get full text

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma by Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, Stewart, A Keith

“…Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor…”
Get full text

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes by Kortüm, K.Martin, Mai, Elias K., Hanafiah, Nur H., Shi, Chang-Xi, Zhu, Yuan-Xiao, Bruins, Laura, Barrio, Santiago, Jedlowski, Patrick, Merz, Maximilian, Xu, Jing, Stewart, Robert A., Andrulis, Mindaugas, Jauch, Anna, Hillengass, Jens, Goldschmidt, Hartmut, Bergsagel, P.Leif, Braggio, Esteban, Stewart, A.Keith, Raab, Marc S.

“…In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation…”
Get full text

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2 by Munshi, Nikhil C., Anderson, Kenneth C., Bergsagel, P. Leif, Shaughnessy, John, Palumbo, Antonio, Durie, Brian, Fonseca, Rafael, Stewart, A. Keith, Harousseau, Jean-Luc, Dimopoulos, Meletios, Jagannath, Sundar, Hajek, Roman, Sezer, Orhan, Kyle, Robert, Sonneveld, Pieter, Cavo, Michele, Rajkumar, S. Vincent, San Miguel, Jesus, Crowley, John, Avet-Loiseau, Hervé

“…A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk…”
Get full text

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma by Kumar, Shaji, Flinn, Ian, Richardson, Paul G., Hari, Parameswaran, Callander, Natalie, Noga, Stephen J., Stewart, A. Keith, Turturro, Francesco, Rifkin, Robert, Wolf, Jeffrey, Estevam, Jose, Mulligan, George, Shi, Hongliang, Webb, Iain J., Rajkumar, S. Vincent

“…Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized…”
Get full text

Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas by Braggio, Esteban, Van Wier, Scott, Ojha, Juhi, McPhail, Ellen, Asmann, Yan W, Egan, Jan, da Silva, Jackline Ayres, Schiff, David, Lopes, M Beatriz, Decker, Paul A, Valdez, Riccardo, Tibes, Raoul, Eckloff, Bruce, Witzig, Thomas E, Stewart, A Keith, Fonseca, Rafael, O'Neill, Brian Patrick

“…Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system. Whether there is a PCNSL-specific…”
Get full text

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides by Egan, Jan B., Shi, Chang-Xin, Tembe, Waibhav, Christoforides, Alexis, Kurdoglu, Ahmet, Sinari, Shripad, Middha, Sumit, Asmann, Yan, Schmidt, Jessica, Braggio, Esteban, Keats, Jonathan J., Fonseca, Rafael, Bergsagel, P. Leif, Craig, David W., Carpten, John D., Stewart, A. Keith

“…The longitudinal evolution of a myeloma genome from diagnosis to plasma cell leukemia has not previously been reported. We used whole-genome sequencing (WGS)…”
Get full text

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study by Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

“…Summary Background The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib…”
Get full text